Levothyroxine is one of the most commonly prescribed medications in the United States. It is used to replace thyroid hormone in people with hypothyroidism, after thyroid surgery, and in some patients with thyroid cancer. The U.S. Food and Drug Administration (FDA) has announced a recall of certain lots of Levothyroxine Sodium Tablets, USP because some tablets may...
Alzheimer's disease is the most common form of dementia, affecting millions of people around the world. While there is still no cure, researchers continue to study lifestyle habits that may help reduce the risk of developing the disease. One area receiving a great deal of attention is diet. A recent review found that following healthy eating patterns, especially the...
The U.S. Food and Drug Administration recently approved the first generic of Xofluza (baloxavir marboxil) tablets, the first single-dose treatment for acute uncomplicated influenza and prophylaxis in patients 5 years of age and older. Approved in time for the 2026–2027 flu season, this approval reflects the Trump Administration’s commitment to increasing the availability of generic drugs.
Diabetes can affect many parts of the body, but one of the most serious complications involves the kidneys. Over time, high blood sugar can damage the tiny blood vessels that help the kidneys filter waste and extra fluid from the blood. This condition is called diabetic kidney disease, also known as diabetic nephropathy. It is the leading cause of chronic kidney disease and kidney failure worldwide.
Hepcludex is prescribed for adults with chronic hepatitis delta virus (HDV) infection who do not have cirrhosis or who have compensated cirrhosis. Hepatitis D is considered the most severe form of viral hepatitis and only occurs in people who also have hepatitis B infection
The U.S. Food and Drug Administration recently issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β thalassemia (TDT). This is the first gene therapy approved for patients aged 2 years and older with SCD. Â